Abstract
References
Kumar PJ, Clark ML. Kumar and Clark’s clinical medicine. 9th ed. Edinburgh: Elsevier, 2017: page 277
Yacyshyn B. Pathophysiology of clostridium difficile-associated diarrhea. Gastroenterol Hepatol (N Y). 2016;12(9):558-60.
Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010 Oct 7;467(7316):711-3. Available from: https://doi.org/10.1038/nature09397
Price AB, Davies DR. Pseudomembranous colitis. J Clin Pathol. 1977;30(1):1-12. Available from: https://doi.org/10.1136/jcp.30.1.1
Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2013;69(4):881-91. Available from: https://doi.org/10.1093/jac/dkt477
Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol. 2006;44(8):2785-91. Available from: https://doi.org/10.1128/JCM.00165-06
Allen SJ, Wareham K, Wang D, et al. A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess. 2013;17(57):1-140. Available from: https://doi.org/10.3310/hta17570
Department of Health. Updated guidance on the diagnosis and reporting on Clostridium difficile. London: DH 2012. Available from: https://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_133016.pdf [Accessed 12 January 2022]
National Institute for Health and Care Excellence. Clostridioides difficile infection: antimicrobial prescribing. NICE; 2009 [updated 23 Jul 2021; cited 12 Jan 2022]. (Clinical guideline [NG199]). Available from: https://www.nice.org.uk/guidance/ng199